Chronic ACE-I/ARB Use Is Associated with Acute Kidney Injury (AKI) in Severe COVID-19 Patients
A retrospective longitudinal cohort study at a French university hospital was conducted to test the "harmful" and "beneficial" ACE-I/ARB hypotheses. 59 biomarkers were screened for in severe COVID-19 patients during their hospital stay, and these data were used to assess the association between chronic ACE-I/ARB use and kidney, lung, heart, and liver dysfunctions and inflammation. It was concluded that this cohort was at an increase risk for acute kidney injury (AKI), and the observed increased in urea nitrogen was associated with the development of acute respiratory failure.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
"Harmful" ACE-I/ARB Hypothesis in Treating SARS-CoV-2 Infection
"Beneficial" ACE-I/ARB Hypothesis in Treating SARS-CoV-2 Infection
Chronic ACE-I/ARB Use Is Associated with Acute Kidney Injury (AKI) in Severe COVID-19 Patients
Rationale in Using ACE Inhibitors (ACE-Is) to Treat or Prevent COVID-19
Controversy of Using ACE Inhibitors (ACE-Is) for Blood Pressure Management in COVID-19
"Beneficial" ACE-I/ARB Hypothesis in Treating SARS-CoV-2 Infection
"Harmful" ACE-I/ARB Hypothesis in Treating SARS-CoV-2 Infection
Chronic ACE-I/ARB Use Is Associated with Acute Kidney Injury (AKI) in Severe COVID-19 Patients